000 01398 a2200409 4500
005 20250516191312.0
264 0 _c20150107
008 201501s 0 0 eng d
022 _a1879-0461
024 7 _a10.1016/j.critrevonc.2013.12.011
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMarech, Ilaria
245 0 0 _aMasitinib (AB1010), from canine tumor model to human clinical development: where we are?
_h[electronic resource]
260 _bCritical reviews in oncology/hematology
_cJul 2014
300 _a98-111 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aBenzamides
650 0 4 _aDogs
650 0 4 _aHumans
650 0 4 _aNeoplasms, Experimental
_xdrug therapy
650 0 4 _aPiperidines
650 0 4 _aProtein Kinase Inhibitors
_xchemistry
650 0 4 _aProto-Oncogene Mas
650 0 4 _aPyridines
650 0 4 _aStructure-Activity Relationship
650 0 4 _aThiazoles
_xchemistry
700 1 _aPatruno, Rosa
700 1 _aZizzo, Nicola
700 1 _aGadaleta, Claudia
700 1 _aIntrona, Marcello
700 1 _aZito, Alfredo Francesco
700 1 _aGadaleta, Cosmo Damiano
700 1 _aRanieri, Girolamo
773 0 _tCritical reviews in oncology/hematology
_gvol. 91
_gno. 1
_gp. 98-111
856 4 0 _uhttps://doi.org/10.1016/j.critrevonc.2013.12.011
_zAvailable from publisher's website
999 _c23431574
_d23431574